<DOC>
	<DOCNO>NCT01391182</DOCNO>
	<brief_summary>You ask take part research study schedule total hip replacement ( arthroplasty ) surgery . The goal study evaluate effectiveness drug , epsilon Aminocaproic Acid ( EACA ) , decrease need patient receive blood surgery . Currently , EACA approve Federal Drug Administration ( FDA ) treat patient bleeding . The investigator plan use EACA prevent bleeding surgery ; use drug mean prevent bleed currently approve FDA .</brief_summary>
	<brief_title>Epsilon Aminocaproic Acid ( EACA ) Reduction Blood Loss Total Hip Arthroplasty ( THA )</brief_title>
	<detailed_description>The goal prospective randomize study evaluate effectiveness drug , epsilon aminocaproic acid ( EACA ) , reduce frequency postoperative blood transfusion follow primary total hip arthroplasty . In institution , 40 % patient preoperative 13.5 g/dl less undergoing total hip arthroplasty require blood transfusion . Fibrinolytic drug EACA tranexamic acid ( TA ) show decrease blood loss surgery decrease likelihood blood transfusion postoperative hospitalization.. Both drug decrease body 's ability break blood clot , thus push balance blood clot formation breakdown towards clot formation . This mechanism decrease amount blood loss surgical procedure . The haemostatic effect EACA investigate multiple study majority show positive effect postoperative hemoglobin level decrease blood transfusion rate . Though several study exist reveal effective safe use perioperative TA , similar drug EACA , paucity information use EACA total joint arthroplasty .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Aminocaproic Acid</mesh_term>
	<criteria>1 . Scheduled primary total hip arthroplasty perform Mayo Clinic 2 . A preoperative hemoglobin 10.0 13.5 1 . A preoperative hemoglobin le 10.0 great 13.5 2 . Revision arthroplasty ; 3 . Arthroplasty perform acute fracture 4 . Inability obtain informed consent ; 5 . Allergy EACA 6 . Pregnancy 7 . History coronary stenting &lt; 6 month 8 . Heart valve replacement ; 9 . Renal disease , 10 . Coagulopathy , DIC , 11. embolic stroke</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Epsilon Aminocaproic Acid</keyword>
	<keyword>blood loss</keyword>
	<keyword>total hip arthroplasty</keyword>
	<keyword>reduction blood transfusion</keyword>
	<keyword>Amicar</keyword>
</DOC>